Teen Inventor Builds $300 AI Wearable to Detect Strabismus, Citing 100 Million Affected Worldwide

A 14-year-old inventor developed a $300 AI-powered wearable, EYEVA, to detect strabismus, a condition affecting an estimated 100 million people globally. The device is currently advancing toward clinical trials to assess its potential for real-time eye drift correction and long-term therapeutic benefits.

A 14-year-old from Cerritos, California, has engineered an artificial intelligence-driven wearable designed to address strabismus, commonly known as crossed eyes. Aaryan Balani developed EYEVA, a visor-style device that provides real-time alerts when a user's eyes drift out of alignment. His motivation stemmed from his own experience with the condition, which developed after a concussion at age five. Balani sought a non-surgical solution to the challenge of maintaining eye alignment.

Balani invested approximately $300 in components to construct the EYEVA wearable. The device underwent five distinct prototype iterations during a four-month development period. EYEVA integrates a 3D-printed visor with small cameras and an AI system trained to identify subtle eye movements. When misalignment is detected, the device emits an alert, prompting user awareness. Balani highlights the condition's prevalence, stating that approximately 100 million people worldwide live with strabismus.

The EYEVA device has earned significant recognition, including top honors at the Orange County Science & Engineering Fair. Industry professionals have acknowledged its viability. Balani is now collaborating with medical professionals to establish formal clinical trials. These trials are critical for rigorously evaluating whether consistent use of the device can lead to improved eye alignment over time. Advancing to human trials necessitates navigating regulatory processes, including adherence to strict guidelines from the Food and Drug Administration (FDA) and careful participant recruitment. The EYEVA device is also currently undergoing the patenting process. The development signifies a step toward accessible, non-surgical interventions for strabismus. Watch for future announcements regarding EYEVA's clinical trial results and its potential impact on a widespread condition.